CME GROUP (NASDAQ: CME)

Start with the main idea: what may be changing, how the clues connect, and what remains uncertain.

The potential opportunity is durable Q4 earnings, not merely the already-known Q3 trading boom. Current contract activity, fee sensitivity and recurring market-data income could support earnings even without another surge in volatility. The stock’s muted response leaves room for that interpretation, but does not prove the shares are mispriced.

Start with the main idea: what may be changing, how the clues connect, and what remains uncertain.

Read the matching explanation in OTR EMERGING DATA.

See the main observations behind the idea, with their important qualifications.

• The company commentary reports October average number of contracts traded each day of 29.671 million contracts, up 17%, through 20 October.

• The 0.5%–1% fee sensitivity applies to annualized clearing and transaction fees at comparable activity, not total revenue.

• Using the disclosed figures, ex-catch-up market-data growth is about 19.9%, adjusted operating-income growth about 14.7% and revenue growth about 13%.

See what could change this interpretation and what still needs to be checked.

October-to-date metals volume fell 55%; the sale-funded repurchase is completed, not a new ongoing catalyst.

There are four unique links; six evidence items ultimately rely on CME. The fee change occurred earlier; this is the fresh commentary’s sensitivity estimate, not a newly announced fee change.

Read the takeaway and the limits that matter before drawing a conclusion.

Its source facts and prices still need independent checks.

Review the information supporting this view and the limits on what it can show.

Checks whether separate pieces of evidence support the same view.

Evidence 1 — October-to-date average daily volume was 29.671 million contracts, up 17%, through 20 October.

Evidence 2 — The fresh commentary estimates October fee changes add 0.5–1% to annualized clearing and transaction fees at comparable activity, not total revenue.

Evidence 3 — Market-data revenue reached $243.1m. Removing disclosed catch-up payments gives approximately 19.9% growth, calculated from company figures.

Evidence 4 — Adjusted operating income rose approximately 14.7%, faster than revenue’s approximately 13% growth; share of revenue left as profit from running the business before interest and tax, after the company’s adjustments reached 69.4%.

Evidence 5 — E-nano futures daily volume increased from 37,000 in September to 66,000 through mid-October.

Evidence 6 — Management reported the number of trading contracts still open above 133 million contracts on 21 October, against approximately 128 million at quarter-end.

Source clocks Evidence 1–5 comes from 21 October results materials. The release was published at 19:00 SGT; the accompanying commentary’s exact upload time is unavailable.

Evidence 6 is from the call beginning 20:30 SGT. Evidence 7 was observed at 22 October, 04:00 and 07:30 SGT.

Historical measurement periods are not being presented as new same-day measurements.

Check the opposing evidence and other explanations that could weaken this view.

Shows evidence and risks that could challenge this view.

October metals volume fell 55%. Return of the OSTTRA proceeds was already completed, so it is not a new ongoing repurchase catalyst.

Compare what people say with the observations, without treating attention as proof.

Compares recorded public discussion with checked market facts.

Research gap: No independent, source-matched sentiment or positioning series was established for this original issue window. Corporate disclosures and a price observation are not a measured crowd-positioning signal.

Read the details behind this part of the research and how they connect to the main idea.

Investments

Read the details behind this part of the research and how they connect to the main idea.

{"currency":"USD","name":"CME Group","symbol":"CME","venue":"NASDAQ"}

Read the details behind this part of the research and how they connect to the main idea.

Read the matching explanation in OTR EMERGING DATA.

Check the opposing evidence and other explanations that could weaken this view.

Read the matching explanation in Chapter 5.

See what changed in the research and why, while keeping earlier recorded views separate.

Recorded public history

Current contract activity, fee sensitivity…

This is the first recorded public view. Further public updates will appear here.

The potential opportunity is durable Q4 earnings, not merely the already-known Q3 trading boom. Current contract activity, fee sensitivity and recurring market-data income could support earnings even without another surge in volatility.

Forecast prepared: 22 Oct, 10:02 SGT Published by OTR: 22 Oct 2026, 11:16 SGT

Check where the information came from, when it was observed and what was verified.

Named assets or actors: CME Group (CME)

Source trail

Any forecast estimate is shown separately with its own source and limitations.

Follow the reasoning from the observations to the proposed result. A possible link is not proof.

OTR’s interpretation: First, October activity provides information beyond the completed third quarter. Second, fee sensitivity and recurring market-data income may support revenue even if volatility stops accelerating.

Check the opposing evidence and other explanations that could weaken this view.

Read the matching explanation in Chapter 5.

Check what was reviewed, what remains uncertain and how much the sources can support.

LEARNING REVIEWED WITH DISCLOSED LIMITS

Choose how to follow this Signal or compare it with other research.

Track this Signal to find it again, compare the evidence, and revisit its recorded outcome.

Explore more Signals →

Find plain meanings for the specialist terms used in this research.